Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sol-Gel Technologies Ltd (SLGL)

Sol-Gel Technologies Ltd (SLGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,949
  • Shares Outstanding, K 2,786
  • Annual Sales, $ 11,540 K
  • Annual Income, $ -10,580 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.10
  • Price/Sales 1.67
  • Price/Cash Flow N/A
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 219.71%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,076.31% on 11/12/24
  • IV Low 0.00% on 06/13/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 19
  • Volume Avg (30-Day) 263
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,588
  • Open Int (30-Day) 1,150

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.70
  • Growth Rate Est. (year over year) +142,614.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.80 +3.53%
on 06/09/25
8.20 -14.20%
on 06/13/25
-0.43 (-5.76%)
since 05/16/25
3-Month
4.02 +75.21%
on 04/10/25
9.00 -21.78%
on 04/30/25
+1.48 (+26.60%)
since 03/14/25
52-Week
3.34 +110.78%
on 08/05/24
16.50 -57.33%
on 12/23/24
-1.76 (-20.01%)
since 06/14/24

Most Recent Stories

More News
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

We expect investors to focus on updates related to Sol-Gel Technologies, Ltd.’s SLGL ability to regain compliance with the recent Nasdaq requirement and other pipeline development activities when it...

MIRM : 49.61 (-0.04%)
SLGL : 7.04 (-6.38%)
PCRX : 24.08 (-0.66%)
Sol-Gel Technologies Approves Mori Arkin as Interim CEO; Provides Update on Clinical Trials and Financial Results

Mori Arkin appointed interim CEO; Sol-Gel reports ongoing clinical trials and recent financial developments.Quiver AI SummarySol-Gel Technologies, Ltd. announced that shareholders approved the appointment...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acneSol-Gel’s U.S. commercialization partner, Galderma, launched...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

TWYNEO will be officially launched for commercial availability in Spring 2022....

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on...

SLGL : 7.04 (-6.38%)
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS...

SLGL : 7.04 (-6.38%)

Business Summary

Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for...

See More

Key Turning Points

3rd Resistance Point 9.49
2nd Resistance Point 8.85
1st Resistance Point 8.18
Last Price 7.04
1st Support Level 6.88
2nd Support Level 6.24
3rd Support Level 5.57

See More

52-Week High 16.50
Fibonacci 61.8% 11.47
Fibonacci 50% 9.92
Fibonacci 38.2% 8.37
Last Price 7.04
52-Week Low 3.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar